Purpose: Short acting b2 agonists are recommended to be used≤ 2 canisters per year. It is
suggested that overuse of b2 agonists will lead to increased morbidity and mortality. This …

Background: Long-acting β-agonists may increase the risk for fatal and nonfatal asthma
exacerbations. Purpose: To assess the risk for severe, life-threatening, or fatal asthma …

Background Overuse of short-acting β 2-agonists (SABA) may indicate poor asthma control
and adverse health outcomes. Contemporary population-based data on use, risk factors and …

A systematic review attempts to summarize the scientific evidence related to treatment,
causation, diagnosis, or prognosis of a specific disease. Meta-analysis refers to that portion …

Background To gain a global perspective on short-acting β2-agonist (SABA) prescriptions
and associated asthma-related clinical outcomes in patients with asthma, we assessed …

Asthma ranks among the most common of chronic diseases in the Western world. Although
modern therapy has improved patient care, asthma still affects 5–10% of the population and …

Review: long-acting beta-agonists increase severe asthma exacerbations and asthma-related
deaths in children and adults. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

OBJECTIVE: To review the more recent literature addressing the issue of whether β2-
agonists can worsen asthma and/or increase the risk of severe exacerbations and death …

Safety of Long-Acting Beta-Agonists — An Urgent Need to Clear the Air | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

The introduction of long-acting beta agonists (LABAs) was considered a major advance in
bronchodilator therapy with evidence that their use led to improved lung function and quality …